GSK Acquires Conjugated Vaccine Expertise With GlycoVaxyn Purchase

The technology could speed the development of prophylactic and therapeutic conjugated vaccines against difficult-to-treat bacterial infections, and the two companies are planning an innovative collaboration that will see GlycoVaxyn retain its autonomy and agility.